Catalent Inc
NYSE:CTLT

Watchlist Manager
Catalent Inc Logo
Catalent Inc
NYSE:CTLT
Watchlist
Price: 63.5 USD 0.03%
Market Cap: 11.5B USD
Have any thoughts about
Catalent Inc?
Write Note

Operating Margin
Catalent Inc

-1.1%
Current
7%
Average
6.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1.1%
=
Operating Profit
-48m
/
Revenue
4.4B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Catalent Inc
NYSE:CTLT
11.5B USD
-1%
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY
-83%
US
Eli Lilly and Co
NYSE:LLY
756.2B USD
35%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
DK
Novo Nordisk A/S
CSE:NOVO B
2.7T DKK
44%
US
Johnson & Johnson
NYSE:JNJ
350.6B USD
28%
US
Merck & Co Inc
NYSE:MRK
252B USD
34%
CH
Roche Holding AG
SIX:ROG
200.1B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
161.8B GBP
21%
CH
Novartis AG
SIX:NOVN
171.5B CHF
31%
US
Pfizer Inc
NYSE:PFE
151.5B USD
22%
Country US
Market Cap 11.5B USD
Operating Margin
-1%
Country JP
Market Cap 776 550.9T JPY
Operating Margin
-83%
Country US
Market Cap 756.2B USD
Operating Margin
35%
Country UK
Market Cap 440.4B GBP
Operating Margin
3%
Country DK
Market Cap 2.7T DKK
Operating Margin
44%
Country US
Market Cap 350.6B USD
Operating Margin
28%
Country US
Market Cap 252B USD
Operating Margin
34%
Country CH
Market Cap 200.1B CHF
Operating Margin
32%
Country UK
Market Cap 161.8B GBP
Operating Margin
21%
Country CH
Market Cap 171.5B CHF
Operating Margin
31%
Country US
Market Cap 151.5B USD
Operating Margin
22%
No Stocks Found

Catalent Inc
Glance View

Market Cap
11.5B USD
Industry
Pharmaceuticals
Economic Moat
None

In the intricate world of pharmaceuticals, Catalent Inc. stands out as a critical player, quietly orchestrating the development and delivery of drugs that impact lives globally. Founded in 2007, Catalent has carved a niche in the field through its commitment to advanced drug delivery technologies and supply chain services. As a contract development and manufacturing organization (CDMO), the company offers a suite of services to pharmaceutical and biotechnology firms, including drug formulation and delivery optimization, biologics development, and clinical supply services. With over 30 facilities worldwide, it acts as a pivotal partner to firms seeking to enhance the effectiveness and accessibility of their therapies without grappling with the complexities of manufacturing and logistics themselves. The crux of Catalent’s business model lies in enabling its clients to bring medical innovations to market effectively and efficiently. By leveraging its expertise in areas such as oral, injectable, and inhalable delivery forms, Catalent ensures that drugs are not only manufactured to the highest standards but are also optimized for patient adherence and effectiveness. The company earns its revenues through long-term contracts by offering continuous support from the early stages of drug development through to commercialization. Catalent drives its growth by staying ahead of industry trends, investing heavily in biologics and gene therapy, which represent high-growth areas in the pharmaceutical industry, thereby ensuring its relevance and significance in an ever-evolving healthcare landscape.

CTLT Intrinsic Value
57.71 USD
Overvaluation 9%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-1.1%
=
Operating Profit
-48m
/
Revenue
4.4B
What is the Operating Margin of Catalent Inc?

Based on Catalent Inc's most recent financial statements, the company has Operating Margin of -1.1%.